What is Survodutide and how does it work?

Survodutide (BI 456906) is a dual GLP-1/Glucagon receptor agonist developed by Boehringer Ingelheim. It activates both receptors to reduce appetite while simultaneously increasing energy expenditure and improving liver fat metabolism.

What makes Survodutide different from Tirzepatide?

While Tirzepatide targets GLP-1 and GIP receptors, Survodutide targets GLP-1 and glucagon receptors. The glucagon component specifically helps with fat oxidation and liver health, making it promising for MASH (fatty liver disease).

What is the Survodutide dosing schedule?

In clinical trials, Survodutide starts at 0.6mg weekly and titrates up through 2.4mg, 3.6mg to a maximum of 4.8mg weekly. Titration typically occurs every 4 weeks based on tolerability.

Is Survodutide FDA approved?

Survodutide is currently in Phase 3 clinical trials for obesity and MASH. It has shown promising results in Phase 2 trials with significant weight loss and liver fat reduction. FDA approval is anticipated pending successful Phase 3 results.

Precision Tool

Survodutide Dosage Calculator

Calculate the exact injection volume for your Survodutide dose. A dual-action agonist targeting both GLP-1 and glucagon receptors.

Input Values

Peptide Vial Size

Total peptide in your vial

Bacteriostatic Water

Amount of BAC water added

Desired Dose

Your target dose per injection

Results

Concentration

5.00 mg/mL

Volume to Inject

0.120 mL

Insulin Syringe

12.0 units

on a 100-unit (1mL) syringe

Total Doses Per Vial

16 doses

Draw to the 12.0 unit mark on your insulin syringe to get exactly 0.6mg of peptide.

Order Research Peptides for Sale

USA-Manufactured, Third Party Tested Peptides
GMP USA Manufactured
Fast Global Shipping
Dedicated Support

Use code PEPTIDEIQ for 15% off any order

Shop Now

Clinical Dosing Guidelines

Product	Indication	Starting Dose	Max Dose
Survodutide (BI 456906)	Obesity/MASH (Phase 3)	0.6mg weekly	4.8mg weekly

Titration Schedule

16+ weeks typical

Current Selection

Week 1-4 — 0.6mg

Titration schedules may vary. Always follow your clinician's guidance.

Survodutide activates both GLP-1 and glucagon receptors for enhanced metabolic effects.

Glucagon component may increase energy expenditure and fat oxidation.

Inject once weekly subcutaneously.

Currently in Phase 3 clinical trials for obesity and MASH.

Frequently Asked Questions

See all GLP-1 medications compared

Our comprehensive reference guide covers every GLP-1 agonist — from approved blockbusters like semaglutide to next-gen candidates in clinical trials. Compare efficacy, side effects, cost, and delivery routes.

Read the Full Guide

Stay Updated

Get the latest peptide research and updates

No spam, unsubscribe anytime